HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

Roche KRAS drug succeeds in head-to-head lung cancer study

The Phase 3 trial compared Roche's divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.

By BioPharma Dive · Jul 2, 2026 · via BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Calling all rising stars in pharma marketing: Nominations open for Fierce feature series
Nominate up-and-coming early-career pharma marketing pros here to be featured in Fierce's "Rising Stars" Q&…
Jul 4, 2026
The WeekFierceBiotech ↗
AstraZeneca pens $1.7B kidney drug discovery pact with go-to Chinese partner CSPC
AstraZeneca has added another piece to its sprawling interface with CSPC Pharmaceutical, paying the Chinese bi…
Jul 4, 2026
FDA Expands Transparency on Competitive Generic Therapy Approvals
The WeekBriefing
FDA Expands Transparency on Competitive Generic Therapy Approvals
The FDA posted an updated list of all approved ANDAs with Competitive Generic Therapy designation, including e…
Jul 4, 2026